Resultados: 8

    Systemic therapy for melanoma: ASCO guideline update

    J. clin. oncol; 41 (30), 2023
    To provide guidance to clinicians regarding the use of systemic therapy for melanoma. American Society of Clinical Oncology convened an Expert Panel and conducted an updated systematic review of the literature. The updated review identified 21 additional randomized trials. Neoadjuvant pembrolizumab was n...

    Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer

    This evaluation uses new cost-effectiveness estimates to update olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (NICE technology appraisal guidance TA831). No new clinical evidence was reviewed. Treatments for BRCA mutation-positive hormone-relapsed meta...

    Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer

    Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults. Commercial arrangement There is a simple discount patient access scheme for olaparib. NHS organisations can get details on the Commercial Access and ...

    Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy

    Evidence-based recommendations on mobocertinib (EXKIVITY) for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy in adults. Commercial arrangement There is a simple discount patient access scheme for mobocertinib. NHS organisations ca...

    Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer

    Cancers (basel); 13 (9), 2021
    The management of patients with triple-negative breast cancer (TNBC) is challenging with several controversies and unmet needs. During the 12th Breast-Gynaecological & Immuno-oncology International Cancer Conference (BGICC) Egypt, 2020, a panel of 35 breast cancer experts from 13 countries voted on conse...

    The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade II Cerebral Gliomas in Adults: Version 2019. 01

    Brain tumor res treat; 7 (2), 2019
    There was no practical guideline for the management of patients with central nervous system tumor in Korea for many years. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, has developed the guideline for glioblastoma. Subsequently, the KSNO guideline for World Hea...

    Guía clínica fibrosis quística

    La Fibrosis Quística (FQ) es la enfermedad autosómica recesiva letal más frecuente en raza blanca. Se transmite de manera autosómica recesiva. Este patrón de herencia implica que una pareja de portadores tiene una probabilidad de 25% de tener un hijo con FQ en cada embarazo. En Chile, de acuerdo con...

    The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs: policy guidance

    This document provides a summary of the evidence and recommendations for the use of SL-LPA for the detection of mutations associated with resistance to fluoroquinolones and SLID in patients with RR-TB and/or MDR-TB. The objectives of this policy guidance are to assess and compare the diagnostic accuracy ...